Keyphrases
Aggressive Histology
16%
Anemia
16%
Chemotherapy
50%
Combination Trials
100%
Complete Response
16%
Complete Response Rate
16%
Drug Regimen
16%
Early Response
16%
Favorable Histology
100%
Follicular non-Hodgkin Lymphoma
50%
High Incidence
16%
Histology
16%
Interferon alpha-2b
100%
Interferon-α (IFN-α)
16%
Intron A
16%
Leukemia
66%
Leukopenia
83%
Life-threatening
16%
Lymphoma
16%
Non-Hodgkin Lymphoma
100%
Oral Cyclophosphamide
100%
Partial Response
33%
Pathology Review
16%
Patient Demographics
16%
Ploughing
16%
Previously Treated Patients
16%
Previously Untreated Patients
66%
Prior Cancer
50%
Prior Chemotherapy
66%
Remission Induction
33%
Response Rate
16%
Thrombocytopenia
16%
Medicine and Dentistry
Anemia
16%
Cyclophosphamide
100%
Interferon
16%
Interferon Alfa 2b
100%
Leukemia
66%
Leukocyte
16%
Leukopenia
83%
Malignant Neoplasm
66%
Non-Hodgkin Lymphoma
100%
Oral
100%
Patient History of Chemotherapy
66%
Patient Population
16%
Recombinant Alpha2b Interferon
16%
Spontaneous Remission
33%
Thrombocytopenia
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha2b Interferon
100%
Anemia
16%
Chemotherapy
50%
Cyclophosphamide
100%
Interferon
16%
Leukemia
66%
Leukopenia
83%
Malignant Neoplasm
66%
Nonhodgkin Lymphoma
100%
Patient History of Chemotherapy
66%
Recombinant Alpha2b Interferon
16%
Remission
33%
Thrombocytopenia
16%
Immunology and Microbiology
Alpha2b Interferon
100%
Cyclophosphamide
100%
Interferon Type I
16%
Leukocyte
16%
Recombinant Alpha2b Interferon
16%